- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00532116
PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
September 18, 2007 updated by: Somerset Pharmaceuticals
Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers
Evaluate the effect of age on the PK of two different doses of EMSAM.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States
- Covance Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or Female, 18 to 45years of age (inclusive) and 65 years of age or older.
- Non-obese as defined by being within 15% of desirable body weight for frame size (Appendix II).
- In general good health as ascertained by physical examination (PE) including measurement of supine and standing vital signs, medical history, clinical laboratory studies, and 12-lead electrocardiogram (ECG).
- Females must have a negative serum pregnancy test during screening confirmed by a negative urine pregnancy screen at the baseline visit. Women of childbearing potential must agree to continuously use a medically acceptable method of birth control during the course of the study. Acceptable birth control methods are hormonal contraceptives, intrauterine devices or double barrier method (a combination of condom plus contraceptive foam). Postmenopausal females will be eligible to participate if their last normal menses was at least one (1) year prior to study entry.
- Able and willing to provide informed consent.
- Able and willing to follow a modified diet.
- Able and willing to follow the requirements of the study; willing to wear a patch, no swimming, no excessive exercise, etc.
Exclusion Criteria:
Presence of significant acute or chronic medical disorder that might complicate or interfere with MAO inhibitor therapy, such as:
- Any cardiovascular or cardiac condition requiring drug treatment. Upon review with Sponsor, subjects with well controlled hypertension or hyperlipidemia will be allowed.
- History of symptomatic orthostatic hypotension, or in the investigator's best clinicaljudgment a clinically significant postural decrease in systolic blood pressure at screening or baseline.
- Type I diabetes mellitus, or poorly controlled Type II diabetes mellitus.
- Malignancy and/or chemotherapy within 1 year prior to screening, other than basal cell carcinoma. Malignancies more than 1 year may not preclude participation and will be reviewed on a case-by-case basis by the Somerset Pharmaceuticals, Inc., medical monitor.
- Any skin condition (e.g., eczema, psoriasis, dyshydrosis) that might interfere with application and adherence of the STS.
- Known or suspected hypersensitivity to selegiline or other MAO inhibitors.
- Any significant immunological, pulmonary, hematologic, endocrine and/or metabolic disease or disorder or severe or acute medical illness, that is, metastatic cancer, brain tumors, decompensated cardiac, hepatic or renal failure.
- Neurological disorders including delirium, history of head trauma, movement disorders, dementia, multiple sclerosis, stroke, within the past 6 months preceding the study.
- Any central nervous system disorder including Alzheimer's disease, Parkinson's disease, epilepsy, or cerebrovascular disease.
- Any psychiatric disorders (except personality disorders).
- Any mood disorder including MDD which is current or relapsed over the past three years.
- ADHD.
- Any conditions that may cause depression including endocrinopathies other than diabetes, lymphoma, pancreatic cancer.
- Any other illness or disorder that in the opinion of the Investigator would place the subject at significant risk or any inability to follow the requirements of the study regarding maintaining scheduled visits or patch applications.
Use of any medication listed below within five half-lives prior to baseline. A longer period of time may be specifically noted for certain medications as indicated:
- All contraindicated medications (see Section 7.1.4.3)
- Psychotropic medication, including centrally active anticholinergics, anticonvulsants, antiparkinsonian agents, fluoxetine (5 weeks), MAOIs (2 weeks), antipsychotics (oral - 60 days; intramuscular - 10 weeks), anxiolytics, vasodilators (exception: Viagra is permitted), cerebral enhancers (acetylcholinesterase inhibitors), psychostimulants, lithium carbonate, nootropics, reserpine, methyldopa (within 30 days), ergot preparations.
- Sympathomimetic drugs, e.g., amphetamines, methylphenidate, dopamine, epinephrine, norepinephrine, over-the-counter (OTC) and prescription nasal decongestants (with the exception of nasal steroids), oral or inhaled sympathomimetic bronchodilators (e.g., albuterol [Proventil], Serevent) and appetite suppressants.
- Any serotonergic drug including sumatriptan succinate (Imitrex), zolmitriptan (Zomig), cyproheptadine (Periactin), methysergide (Sansert) or other agonists or antagonists of serotonin receptors.
- Meperidine (Demerol), or other opioids.
- R(-)tryptophan, metoclopramide.
- St. John's wort / hypericum within two (2) weeks and other herbal supplements
- Dietary supplements containing tyramine and/or ephedrine.
- Presence of an Axis-II disorder that makes it unlikely that the subject will be compliant.
- Presence or history of bipolar disorder or psychotic disorder.
- Serious risk of suicide.
- History of substance abuse, including alcohol abuse as defined by DSM-IV criteria, within the past 12 months.
- Current use of tobacco products.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
EMSAM 6mg
|
STS 6mg/24hr
|
Active Comparator: B
EMSAM (Selegiline Transdermal System) 12mg
|
EMSAm 12mg/24Hr
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose Proportionality of PK parameters and EMSAM release characteristics.
Time Frame: 33 days
|
33 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
September 18, 2007
First Submitted That Met QC Criteria
September 18, 2007
First Posted (Estimate)
September 19, 2007
Study Record Updates
Last Update Posted (Estimate)
September 19, 2007
Last Update Submitted That Met QC Criteria
September 18, 2007
Last Verified
September 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S9303-P0601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on EMSAM (Selegiline Transdermal System) 6mg
-
Somerset PharmaceuticalsCompleted
-
Somerset PharmaceuticalsCompletedMajor Depressive DisorderUnited States
-
New York State Psychiatric InstituteTerminated
-
Mood and Anxiety Research, IncCompletedBorderline Personality DisorderUnited States
-
Somerset PharmaceuticalsCompletedMajor DepressionUnited States
-
Stanford UniversityNational Institute on Drug Abuse (NIDA)Completed
-
National Institute on Drug Abuse (NIDA)VA Office of Research and DevelopmentCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Northwestern University3MCompletedHealthyUnited States
-
Midwest Biomedical Research FoundationNational Institute on Drug Abuse (NIDA)CompletedCocaine Use DisordersUnited States